Jan 08, 2018
Ionis' Inotersen NDA Accepted for Priority Review by the FDA
Dec 21, 2017
Ionis Pharmaceuticals Announces The Initiation Of A Clinical Study Of Its First Orally Delivered Antisense Drug For The Treatment Of Gastrointestinal Disorders
Dec 15, 2017
Ionis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dec 11, 2017
Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington's Disease
Dec 07, 2017
Ionis Pharmaceuticals to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
Nov 09, 2017
Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure
Nov 08, 2017
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 07, 2017
Ionis Announces Management Transitions
Nov 07, 2017
Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2017
Nov 06, 2017
Ionis Announces Submission of New Drug Application (NDA) for Inotersen to the U.S. FDA
Nov 03, 2017
Ionis Announces Submission of Marketing Authorization Application for Inotersen to the European Medicines Agency
Nov 02, 2017
Ionis Presents New Data from NEURO-TTR Study at European ATTR Amyloidosis Meeting
Nov 01, 2017
Ionis to Present Inotersen NEURO-TTR Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting
Oct 27, 2017
Ionis and Biogen Win Prestigious Prix Galien Best Biotechnology Product Award for SPINRAZA
Oct 24, 2017
Ionis Pharmaceuticals to Hold Third Quarter 2017 Financial Results Webcast
Oct 18, 2017
Ionis Enters into Collaboration with Seventh Sense Biosystems to Support Development of Improved Blood Collection and Diagnostic Device
Oct 13, 2017
Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer's Disease
Sep 11, 2017
New Data Presented at European Society for Medical Oncology Meeting Demonstrate Antitumor Activity with IONIS-STAT3-2.5 Rx in Combination with Imfinzi
Aug 30, 2017
Ionis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen
Aug 24, 2017
Ionis Recommends Shareholders Reject The Below-The-Market Mini-Tender Offer By TRC Capital Corporation